Zeki Üstüner

705 total citations
24 papers, 562 citations indexed

About

Zeki Üstüner is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Zeki Üstüner has authored 24 papers receiving a total of 562 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 7 papers in Molecular Biology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Zeki Üstüner's work include Hepatocellular Carcinoma Treatment and Prognosis (4 papers), Peptidase Inhibition and Analysis (4 papers) and Cancer Treatment and Pharmacology (3 papers). Zeki Üstüner is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (4 papers), Peptidase Inhibition and Analysis (4 papers) and Cancer Treatment and Pharmacology (3 papers). Zeki Üstüner collaborates with scholars based in Türkiye and United States. Zeki Üstüner's co-authors include Burak Sakar, Nuri Faruk Aykan, Sezer Sağlam, Zafer Gülbaş, Olga Meltem Akay, Zerrin Cantürk, Fezan Mutlu, Mert Başaran, Hakan Karagöl and Erkan Topuz and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Retina.

In The Last Decade

Zeki Üstüner

22 papers receiving 549 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Zeki Üstüner Türkiye 11 219 124 121 115 86 24 562
Mustafa Altınbaş Türkiye 12 202 0.9× 120 1.0× 103 0.9× 145 1.3× 36 0.4× 47 670
Sigrun Badrnya Austria 10 90 0.4× 47 0.4× 93 0.8× 196 1.7× 69 0.8× 16 593
Masahito Tanimizu Japan 15 132 0.6× 190 1.5× 201 1.7× 235 2.0× 55 0.6× 49 734
Fumiharu Miura Japan 12 78 0.4× 55 0.4× 153 1.3× 127 1.1× 41 0.5× 34 592
Chengyong Qin China 18 151 0.7× 102 0.8× 187 1.5× 396 3.4× 156 1.8× 51 847
Chi‐Jen Chang Taiwan 15 43 0.2× 61 0.5× 159 1.3× 138 1.2× 54 0.6× 42 574
Lijie He China 14 111 0.5× 77 0.6× 100 0.8× 311 2.7× 49 0.6× 26 753
Soichiro Takai Japan 16 488 2.2× 181 1.5× 316 2.6× 83 0.7× 151 1.8× 40 792
Kenzo Sugi Japan 5 116 0.5× 72 0.6× 188 1.6× 131 1.1× 100 1.2× 13 778
Felix Mehrhof Germany 10 53 0.2× 39 0.3× 113 0.9× 225 2.0× 35 0.4× 23 630

Countries citing papers authored by Zeki Üstüner

Since Specialization
Citations

This map shows the geographic impact of Zeki Üstüner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zeki Üstüner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zeki Üstüner more than expected).

Fields of papers citing papers by Zeki Üstüner

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zeki Üstüner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zeki Üstüner. The network helps show where Zeki Üstüner may publish in the future.

Co-authorship network of co-authors of Zeki Üstüner

This figure shows the co-authorship network connecting the top 25 collaborators of Zeki Üstüner. A scholar is included among the top collaborators of Zeki Üstüner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zeki Üstüner. Zeki Üstüner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zengin, Nurullah, et al.. (2017). A new angiogenesis prognostic index with VEGFA, PlGF, and angiopoietin1 predicts survival in patients with advanced gastric cancer. TURKISH JOURNAL OF MEDICAL SCIENCES. 47(2). 399–406. 12 indexed citations
2.
Üstüner, Zeki, et al.. (2012). Evaluating coagulation disorders in the use of bevacizumab for metastatic colorectal cancer by thrombelastography. Medical Oncology. 29(5). 3125–3128. 10 indexed citations
3.
Üstüner, Zeki, et al.. (2012). Importance of serum VEGF and basic FGF levels in determining response to treatment and survival in patients with metastatic colorectal cancer.. Journal of Clinical Oncology. 30(15_suppl). e21050–e21050. 3 indexed citations
4.
Oğuz, Hilal, et al.. (2011). Matrix metalloproteinase-9 decreased after chemotherapy in patients with non-small cell lung cancer. Tumori Journal. 97(3). 286–289. 9 indexed citations
5.
Oğuz, Hilal, et al.. (2011). Matrix metalloproteinase-9 decreased after chemotherapy in patients with non-small cell lung cancer.. PubMed. 97(3). 286–9. 7 indexed citations
6.
Altundağ, Kadri, Semra Paydaş, Gül Başaran, et al.. (2011). Nine versus 52 weeks of adjuvant trastuzumab in early breast cancer: An observational study of the Turkish Oncology Group.. Journal of Clinical Oncology. 29(15_suppl). 629–629. 3 indexed citations
7.
Saip, Pınar, Burçak Vural, Ayşe Demirkan, et al.. (2010). Association between glutathione s-transferase P1 polymorphisms and time to tumor progression in small cell lung cancer patients.. Journal of Clinical Oncology. 28(15_suppl). e12041–e12041. 1 indexed citations
8.
Akay, Olga Meltem, Zeki Üstüner, Zerrin Cantürk, Fezan Mutlu, & Zafer Gülbaş. (2008). Laboratory investigation of hypercoagulability in cancer patients using rotation thrombelastography. Medical Oncology. 26(3). 358–364. 88 indexed citations
9.
Üstüner, Zeki, Pınar Saip, Vildan Yasasever, et al.. (2008). Prognostic and predictive value of vascular endothelial growth factor and its soluble receptors, VEGFR-1 and VEGFR-2 levels in the sera of small cell lung cancer patients. Medical Oncology. 25(4). 394–399. 32 indexed citations
10.
Sakar, Burak, Mert Başaran, Andaç Argon, et al.. (2007). XELOX Followed by XELIRI or the Reverse Sequence in Advanced Colorectal Cancer. Oncology. 73(5-6). 298–304. 7 indexed citations
11.
Taş, Faruk, Zeki Üstüner, Gülbeyaz Can, et al.. (2005). The prevalence and determinants of the use of complementary and alternative medicine in adult Turkish cancer patients. Acta Oncologica. 44(2). 161–167. 66 indexed citations
12.
Vural, Burçak, Pınar Saip, Yao‐Tseng Chen, et al.. (2005). Frequency of SOX Group B (SOX1, 2, 3) and ZIC2 antibodies in Turkish patients with small cell lung carcinoma and their correlation with clinical parameters. Cancer. 103(12). 2575–2583. 66 indexed citations
13.
Üstüner, Zeki, Mert Başaran, Talat Kırış, et al.. (2004). Skull Base Plasmacytoma in a Patient with Light Chain Myeloma. Skull base. 13(3). 167–172. 33 indexed citations
14.
Taş, Faruk, Vildan Yasasever, Derya Duranyıldız, et al.. (2004). Clinical Value of Protein S100 and Melanoma-Inhibitory Activity (MIA) in Malignant Melanoma. American Journal of Clinical Oncology. 27(3). 225–228. 12 indexed citations
15.
Sakar, Burak, Hakan Karagöl, Mahmut Gümüş, et al.. (2004). Timing of Death From Tumor Recurrence After Curative Gastrectomy for Gastric Cancer. American Journal of Clinical Oncology. 27(2). 205–209. 45 indexed citations
16.
Sakar, Burak, Zeki Üstüner, Hakan Karagöl, et al.. (2004). Prognostic Features and Survival of Inoperable Hepatocellular Carcinoma in Turkish Patients With Cirrhosis. American Journal of Clinical Oncology. 27(5). 489–493. 17 indexed citations
17.
Taş, Faruk, et al.. (2004). MASSIVE AND ISOLATED METASTASES TO SPLEEN OF UVEAL MALIGNANT MELANOMA. Retina. 24(1). 170–172. 3 indexed citations
18.
Vural, Burçak, Zeki Üstüner, Pınar Saip, et al.. (2004). Immunoreactivity to SOX-1, -2, -3 and ZIC2 antigens and correlation to survival in small cell lung cancer (SCLC). Journal of Clinical Oncology. 22(14_suppl). 7159–7159.
19.
20.
Kabukçuoğlu, Sare, et al.. (1998). Bone Marrow Involment and Myelofibrosis in Hudgkin's Disase. DergiPark (Istanbul University).

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mustafa Altınbaş Breakdown of academic impact, for papers by Sigrun Badrnya Breakdown of academic impact, for papers by Masahito Tanimizu Breakdown of academic impact, for papers by Fumiharu Miura Breakdown of academic impact, for papers by Chengyong Qin Breakdown of academic impact, for papers by Chi‐Jen Chang Breakdown of academic impact, for papers by Lijie He Breakdown of academic impact, for papers by Soichiro Takai Breakdown of academic impact, for papers by Kenzo Sugi Breakdown of academic impact, for papers by Felix Mehrhof
Rankless by CCL
2026